Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry

Harjai, Kishore J.; Shenoy, Chetan; Orshaw, Pamela; Boura, Judy

doi:10.1136/hrt.2009.169896

Cited by 31 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Harjai et al [44] in a prospective observation, demonstrated that the continuation of DAPT beyond 12 months in patients undergoing PCI of native coronaries, who survived with no major adverse cardiac events (MACE), did not confer long-term protection from death or myocardial infarction. Ferreira-Gonzales et al [45] has suggested that the discontinuation of DAPT after DES implantation within 1 year following the invasive procedure is not significantly associated with the risk of an occurrence of MACE during the follow-up.…”

Section: Adherence After Ami Treated By Pcimentioning

confidence: 99%

Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications

Świeczkowski

Mogielnicki²,

Cwalina

et al. 2013

Cardiol J

View full text Add to dashboard Cite

show abstract

Section: Adherence After Ami Treated By Pcimentioning

confidence: 99%

Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications

Świeczkowski

Mogielnicki²,

Cwalina

et al. 2013

Cardiol J

View full text Add to dashboard Cite

show abstract

“…The details of the design of this registry have been described previously. 14 Demographic, clinical, and procedural data are collected in accordance with the American College of Cardiology National Cardiovascular Data Registry definitions and entered in an Excel spreadsheet. After discharge from the hospital, all patients are prescribed aspirin to be continued indefinitely.…”

Section: Guthrie Pci Registrymentioning

confidence: 99%

Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention

Harjai

Shenoy

Orshaw

et al. 2011

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background— The concomitant use of proton pump inhibitors (PPIs) with clopidogrel is suspected to be associated with an adverse impact on clinical outcomes in patients with coronary artery disease. We sought to evaluate whether the use of PPIs with clopidogrel was associated with worse clinical outcomes after percutaneous coronary intervention (PCI) compared with the use of clopidogrel alone. Methods and Results— We studied 2651 consecutive patients discharged alive after coronary stenting for stable or unstable coronary artery disease between 2001 and 2007. All patients received aspirin indefinitely and a thienopyridine for 1 to 12 months. Patients were categorized into 2 groups: those taking a PPI [PPI (+), n=751] and those not taking a PPI [PPI (−), n=1900] at discharge. The primary end points were the 6-month incidence of major adverse cardiovascular events (MACE) (composite of death, myocardial infarction, target vessel revascularization, and stent thrombosis) and net adverse clinical events (NACE) (composite of MACE and thrombolysis in myocardial infarction major or minor bleeding), which were evaluated using propensity-adjusted Cox regression analysis. In addition, propensity-matched analysis was performed in 685 pairs of patients. The PPI (+) group was older and had more comorbid conditions than the PPI (−) group. In propensity-adjusted as well as propensity-matched analyses, the use of PPIs was not associated with an increased risk of MACE or NACE. Conclusions— The use of PPIs with dual antiplatelet therapy was not associated with any adverse influence on MACE or NACE after PCI.

show abstract

“…The impact of prolonged DAPT beyond 12 months has been evaluated in a registry study, which found no additional protection against death or MI compared with DAPT for ≤12 months. 84 This was confirmed in a randomised trial of continuing aspirin and clopidogrel versus monotherapy with aspirin in 2701 patients who had already received DAPT for 12 months after PCI. 85 At 2-years' follow-up, rates of MI and death were similar in the two groups (1.8% vs 1.2%), providing support for the guideline recommendation to continue DAPT for 12 months after PCI with DES.…”

Section: Stent Thrombosismentioning

confidence: 64%

Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology

Henderson

2011

Revista Portuguesa de Cardiologia

View full text Add to dashboard Cite

Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry

Abstract: In patients who undergo successful native coronary PCI and survive event-free for at least 12 months, continuation of dual antiplatelet therapy beyond 12 months does not confer long-term protection from death or MI.

Cited by 31 publications

References 29 publications

Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications

Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications

Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention

Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology

Contact Info

Product

Resources

About